Literature DB >> 15562138

Acute rhabdomyolysis associated with ofloxacin/levofloxacin therapy.

Shu-Hwa Hsiao1, Chia-Ming Chang, Chao-Jung Tsao, Yu-Yun J Lee, May-Ying Hsu, Ta-Jen Wu.   

Abstract

OBJECTIVE: To report a case of ofloxacin/levofloxacin-induced rhabdomyolysis and to compare other reported cases from the literature. CASE
SUMMARY: A 19-year-old male patient developed ofloxacin/levofloxacin-induced rhabdomyolysis during admission for periorbital cellulitis. Symptoms of myalgia, weakness, and swelling of the arms developed after 3 days of treatment with ofloxacin 800 mg/day. Laboratory analysis confirmed the presence of urine myoglobin (381.2 microg/L) and a marked increase in serum myoglobin (590.8 microg/L), along with marked elevations in serum creatine kinase (up to 16 546 IU/L). DISCUSSION: In addition to ruling out other possible etiologic factors one by one, we assessed the probability of ofloxacin/levofloxacin-induced rhabdomyolysis by observing the close time relationship between drug administration and the development of symptoms/signs, as well as the close time relationship between drug withdrawal and the disappearance of symptoms/signs. An objective causality assessment by use of the Naranjo probability scale revealed that the adverse drug reaction was probable.
CONCLUSIONS: Although ofloxacin/levofloxacin-induced rhabdomyolysis appears to be rare, patients with muscle pain, swelling, or weakness during therapy should be closely monitored for this adverse effect.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15562138     DOI: 10.1345/aph.1E285

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  8 in total

1.  Moxifloxacin-induced rhabdomyolysis.

Authors:  S Sanjith; A Raodeo; A Clerk; R Pandit; D R Karnad
Journal:  Intensive Care Med       Date:  2012-02-10       Impact factor: 17.440

2.  Rhabdomyolysis in a patient treated with linezolid for extensively drug-resistant tuberculosis.

Authors:  Matthew W Carroll; Hongjo Choi; Seonyeong Min; Soohee Hwang; Hyeeun Park; Taeksun Song; Yumi Park; Han-Seung Jeon; Lisa C Goldfeder; Laura E Via; Janette Lebron; Boyoung Jin; Ying Cai; Clifton E Barry; Myungsun Lee
Journal:  Clin Infect Dis       Date:  2012-03-15       Impact factor: 9.079

3.  Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis.

Authors:  Santiago Vilar; Rave Harpaz; Herbert S Chase; Stefano Costanzi; Raul Rabadan; Carol Friedman
Journal:  J Am Med Inform Assoc       Date:  2011-09-21       Impact factor: 4.497

4.  Fluoroquinolone use in a child associated with development of osteochondritis dissecans.

Authors:  John C Jacobs; Kevin G Shea; Julia Thom Oxford; James L Carey
Journal:  BMJ Case Rep       Date:  2014-09-16

5.  A case of rhabdomyolysis in which levetiracetam was suspected as the cause.

Authors:  Hisanao Akiyama; Yoshiteru Haga; Naoshi Sasaki; Toshiyuki Yanagisawa; Yasuhiro Hasegawa
Journal:  Epilepsy Behav Case Rep       Date:  2014-09-16

6.  Acute rhabdomyolysis associated with coadministration of levofloxacin and simvastatin in a patient with normal renal function.

Authors:  Maria Paparoupa; Sebastian Pietrzak; Adrian Gillissen
Journal:  Case Rep Med       Date:  2014-07-22

7.  Metabolic effects as a cause of myotoxic effects of fluoroquinolones.

Authors:  Thomas Metterlein; Frank Schuster; Martin Hager; Norbert Roewer; Martin Anetseder
Journal:  Indian J Pharmacol       Date:  2015 Nov-Dec       Impact factor: 1.200

8.  Mining and visualizing high-order directional drug interaction effects using the FAERS database.

Authors:  Xiaohui Yao; Tiffany Tsang; Qing Sun; Sara Quinney; Pengyue Zhang; Xia Ning; Lang Li; Li Shen
Journal:  BMC Med Inform Decis Mak       Date:  2020-03-18       Impact factor: 2.796

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.